^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Somatostatin analogue

    Related drugs:
    Associations

    News

    Trials
    1m
    ASTERIA: ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (clinicaltrials.gov)
    P2, N=60, Recruiting, Alexion Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IGF1 (Insulin-like growth factor 1)
    4ms
    Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)
    P3, N=274, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)
    5ms
    Clinical and biological determinants of short and long term responses to somatostatin analogue therapy in acromegaly patients. (PubMed, Br J Neurosurg)
    Baseline GH and IGF-1 levels were not significantly predictive of treatment response (p > 0.05). In acromegaly patients not cured by surgery, hyperintense MRI features, sparse granulation, and diabetes at diagnosis predict reduced short and long term responses to SSA therapy.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    5ms
    LUTARTERIAL: Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (clinicaltrials.gov)
    P2, N=23, Recruiting, University Hospital, Bordeaux | Trial completion date: Sep 2024 --> Mar 2027 | Trial primary completion date: Mar 2023 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    6ms
    ASTERIA: ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Alexion Pharmaceuticals, Inc.
    New P2 trial
    |
    IGF1 (Insulin-like growth factor 1)
    7ms
    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov)
    P3, N=259, Active, not recruiting, ITM Solucin GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
    7ms
    A Phase 1 Study of TE-8214 Solution in Healthy Volunteers (clinicaltrials.gov)
    P1, N=32, Completed, Immunwork, Inc. | Active, not recruiting --> Completed
    Trial completion
    7ms
    OXTEND™-03: A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (clinicaltrials.gov)
    P3, N=119, Recruiting, Debiopharm International SA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IGF1 (Insulin-like growth factor 1)
    |
    octreotide 3-month extended release (Debio 4126)
    8ms
    Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics (clinicaltrials.gov)
    P2/3, N=103, Active, not recruiting, Mayo Clinic | Enrolling by invitation --> Active, not recruiting | N=400 --> 103 | Trial primary completion date: Dec 2025 --> Feb 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    8ms
    OXTEND™-03: A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (clinicaltrials.gov)
    P3, N=119, Not yet recruiting, Debiopharm International SA
    New P3 trial
    |
    IGF1 (Insulin-like growth factor 1)
    |
    octreotide 3-month extended release (Debio 4126)
    9ms
    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). (PubMed, BMC Cancer)
    The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.
    Clinical • Clinical protocol • Journal • HEOR
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    everolimus • Solucin (177Lu-edotreotide)
    9ms
    Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. (PubMed, Acta Pharm Sin B)
    Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (denoted as 177Lu-EB-TATE) is characterized by a higher tumor uptake and residence time in preclinical models and in patients with metastatic NETs. Preliminary PRRT efficacy results showed an 83% disease control rate and a 42% overall response rate after two 177Lu-LNC1010 treatment cycles. These encouraging findings warrant further investigations through multicenter, prospective, and randomized controlled trials.
    P1 data • Preclinical • Journal
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    177Lu-EBTATE • 177Lu-LNC1010